Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS) has successfully completed enrollment of 9 additional patients in its TakeAim Leukemia study ahead of schedule, addressing the FDA's requirements to resolve a partial clinical hold. Data from these patients is anticipated in Q2 2023, with discussions planned with the FDA for Q3 regarding the recommended Phase 2 dose for emavusertib, an IRAK-4 inhibitor. Financially, Curis reported a net loss of $56.7 million for 2022, with revenues slightly down to $10.2 million compared to the prior year. As of December 31, 2022, the company holds $85.6 million in cash, expected to fund operations into 2025.
Curis, Inc. (NASDAQ: CRIS) has announced the rescheduling of its fourth quarter business update and investor conference call from March 9, 2023, to March 13, 2023. The update will be released at 8:00 a.m. ET, followed by the conference call at 8:30 a.m. ET. To access the call, investors can dial (888)-346-6389 or (412)-317-5252 for international calls, or join via the Curis website. The company focuses on innovative cancer therapeutics, collaborating with partners like Aurigene and Genentech, currently testing drug candidates in various trials, including a Phase 1/2 trial for its IRAK4 inhibitor, emavusertib.
Curis, Inc. (NASDAQ: CRIS) announces it will release its fourth quarter 2022 financial results on March 9, 2023, following the close of U.S. markets. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results. Curis focuses on developing innovative cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech. Notably, the FDA has placed a partial clinical hold on Curis's TakeAim Leukemia trial, affecting patient enrollment for some phases. For more details, visit Curis's website.
Curis announced positive updates from the Phase 1a study of emavusertib (CA-4948) in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (hrMDS). In patients with FLT3 mutations, a 29% complete remission (CR) rate was noted, while those with spliceosome mutations saw a CR/CRh rate of 22%. Additionally, an overall response rate (ORR) of 45% was recorded in hrMDS patients. Emavusertib is also being evaluated in combination with venetoclax. The company plans to discuss a recommended Phase 2 dose with the FDA by mid-2023.
Curis, Inc. (NASDAQ: CRIS) will host a webcast on December 12, 2022, at 10:00 a.m. ET, to discuss new data from the TakeAim Leukemia trial involving emavusertib, presented at the 64th American Society of Hematology Annual Meeting. This session will include results from 28 additional evaluable AML/MDS patients, focusing on those treated with emavusertib as monotherapy and in combination with venetoclax. The call will feature leadership presentations and a Q&A session.
Curis, Inc. (NASDAQ: CRIS) reported its third-quarter 2022 business update, focusing on the development of emavusertib for relapsed or refractory acute myeloid leukemia. The company will present additional data at ASH 2022, highlighting a total of 24 patients treated. Curis plans to concentrate resources on emavusertib, reducing its workforce by approximately 30% and extending its cash runway into 2025. Financially, Curis reported a net loss of $13.3 million for Q3 2022, with net revenues of $2.8 million. Cash and investments totaled $98.7 million as of September 30, 2022.
Curis, Inc. (NASDAQ: CRIS) announced its participation in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) in Boston, showcasing three significant research posters. Key highlights include a presentation on emavusertib, an IRAK4 inhibitor, detailing its therapeutic potential for melanoma brain metastases. Additionally, two presentations on CI-8993, an anti-VISTA antibody, focus on its pharmacokinetic and pharmacodynamic profiles. These presentations aim to enhance understanding of their roles in cancer treatment.
Curis, Inc. (NASDAQ: CRIS) plans to report its third quarter 2022 financial results on November 9, 2022, after U.S. market closure. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results. Curis is known for developing innovative cancer therapeutics, including collaborations on various immuno-oncology projects. Notably, the TakeAim Leukemia trial of emavusertib is on a partial clinical hold, impacting new patient enrollment.
On October 3, 2022, Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for 121,650 shares to two new employees. These options have an exercise price equal to the stock's closing price on that date, a 10-year term, and vest over four years. This grant was made outside of the company's existing stock incentive plan as a material inducement for employment. Curis specializes in innovative cancer therapeutics, including partnerships for developing novel treatments like emavusertib, currently in clinical trials for hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) will host the 1st Symposium on IRAK4 in Cancer on October 7, 2022, from 9:00 am to 1:00 pm ET. The virtual event, led by renowned experts, will explore the role of IRAK4, a promising target for cancer treatment, particularly in hematologic malignancies. CEO James Dentzer emphasized IRAK4's potential as an immunotherapy target. The agenda includes discussions on IRAK4 biology, mechanisms in cancer, and therapeutic strategies involving IRAK4 inhibitors.